GB201914165D0 - Hybrid antibody - Google Patents

Hybrid antibody

Info

Publication number
GB201914165D0
GB201914165D0 GB201914165A GB201914165A GB201914165D0 GB 201914165 D0 GB201914165 D0 GB 201914165D0 GB 201914165 A GB201914165 A GB 201914165A GB 201914165 A GB201914165 A GB 201914165A GB 201914165 D0 GB201914165 D0 GB 201914165D0
Authority
GB
United Kingdom
Prior art keywords
hybrid antibody
antibody
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201914165A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epsilogen Ltd
Original Assignee
Igem Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igem Therapeutics Ltd filed Critical Igem Therapeutics Ltd
Priority to GB201914165A priority Critical patent/GB201914165D0/en
Publication of GB201914165D0 publication Critical patent/GB201914165D0/en
Priority to EP20789871.9A priority patent/EP4041397A1/en
Priority to US17/764,854 priority patent/US20220380482A1/en
Priority to CA3152084A priority patent/CA3152084A1/en
Priority to AU2020360962A priority patent/AU2020360962A1/en
Priority to EP20789872.7A priority patent/EP4041398A1/en
Priority to CN202080082725.3A priority patent/CN115175736A/en
Priority to BR112022006364A priority patent/BR112022006364A2/en
Priority to CA3152097A priority patent/CA3152097A1/en
Priority to US17/764,850 priority patent/US20230059181A1/en
Priority to MX2022004073A priority patent/MX2022004073A/en
Priority to PCT/EP2020/077609 priority patent/WO2021064153A1/en
Priority to JP2022520650A priority patent/JP2022552805A/en
Priority to KR1020227009817A priority patent/KR20220070215A/en
Priority to PCT/EP2020/077608 priority patent/WO2021064152A1/en
Priority to JP2022520761A priority patent/JP2022550976A/en
Priority to CN202080083349.XA priority patent/CN114761087A/en
Priority to AU2020358898A priority patent/AU2020358898A1/en
Ceased legal-status Critical Current

Links

GB201914165A 2019-10-01 2019-10-01 Hybrid antibody Ceased GB201914165D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GB201914165A GB201914165D0 (en) 2019-10-01 2019-10-01 Hybrid antibody
AU2020358898A AU2020358898A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
CA3152097A CA3152097A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
MX2022004073A MX2022004073A (en) 2019-10-01 2020-10-01 Hybrid antibody.
CA3152084A CA3152084A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
AU2020360962A AU2020360962A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
EP20789872.7A EP4041398A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
CN202080082725.3A CN115175736A (en) 2019-10-01 2020-10-01 Hybrid antibodies
BR112022006364A BR112022006364A2 (en) 2019-10-01 2020-10-01 HYBRID ANTIBODY
EP20789871.9A EP4041397A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
US17/764,850 US20230059181A1 (en) 2019-10-01 2020-10-01 IgE Antibody with Fcgamma Receptor binding
US17/764,854 US20220380482A1 (en) 2019-10-01 2020-10-01 IgE Antibody with FcRn binding
PCT/EP2020/077609 WO2021064153A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
JP2022520650A JP2022552805A (en) 2019-10-01 2020-10-01 hybrid antibody
KR1020227009817A KR20220070215A (en) 2019-10-01 2020-10-01 hybrid antibody
PCT/EP2020/077608 WO2021064152A1 (en) 2019-10-01 2020-10-01 Hybrid antibody
JP2022520761A JP2022550976A (en) 2019-10-01 2020-10-01 hybrid antibody
CN202080083349.XA CN114761087A (en) 2019-10-01 2020-10-01 Hybrid antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201914165A GB201914165D0 (en) 2019-10-01 2019-10-01 Hybrid antibody

Publications (1)

Publication Number Publication Date
GB201914165D0 true GB201914165D0 (en) 2019-11-13

Family

ID=68538871

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201914165A Ceased GB201914165D0 (en) 2019-10-01 2019-10-01 Hybrid antibody

Country Status (1)

Country Link
GB (1) GB201914165D0 (en)

Similar Documents

Publication Publication Date Title
IL289112A (en) Anti-tigit antibodies
SG11202108141VA (en) Novel cd40-binding antibodies
IL291068A (en) Anti-cd73 antibodies
IL284584A (en) Anti-tigit antibodies
ZA202108836B (en) Anti-epha4 antibody
GB201905150D0 (en) Ant-ige antibodies
GB2581174B (en) Antibodies against hEPCR
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
GB202105110D0 (en) Anti-CD73 antibodies
EP4081539A4 (en) Novel anti-fgfr2b antibodies
EP4081547A4 (en) Novel anti-fgfr2b antibodies
EP4081546A4 (en) Novel anti-fgfr2b antibodies
GB202014851D0 (en) SARS-COV-2 antibodies
GB201917059D0 (en) Hybrid antibody
GB201914165D0 (en) Hybrid antibody
GB202008248D0 (en) Hybrid Antibody
GB201919062D0 (en) Antibody
GB201912008D0 (en) Antibody
GB201919280D0 (en) Antibodies
SG11201913540VA (en) Anti-Podoplanin Antibody
AU2019033V (en) AMDB002 Agapanthus hybrid
AU2019034V (en) WP001 Agapanthus hybrid
GB201900983D0 (en) Antibody

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)